Tagged with EG

Switzerland New Idorsia CEO Srishti Gupta is emphasising “financial discipline” as she looks to turn around the fortunes of one of Europe’s top biotechs.   Challenging Times Gupta, who spent almost two decades at consultancy firm McKinsey, inherits a company that managed to launch three drugs in its first seven years…

Switzerland Dr Srishti Gupta brings a distinctive combination of medical training, health policy insight, and strategic consulting to her role as CEO of Idorsia Pharmaceuticals. A Harvard-trained biochemist and physician, she spent 18 years at McKinsey & Company advising life sciences and global health clients. Committed to reducing healthcare inequities and…

Hong Kong Since our last conversation with Tony Cheng in mid-2024, Merck Hong Kong has entered a new phase of consolidation and growth. The affiliate has strengthened its team, accelerated its adoption of AI, and deepened collaborations with the Hong Kong Science and Technology Parks. At the same time, Cheng continues to…

Europe The EU’s Health Technology Assessment Regulation (HTAR), which kicked off in January 2025, has launched joint clinical assessments (JCAs) for oncology and advanced therapies; yet six months in, implementation remains rocky, communication is patchy, and the wider impact on access and innovation is still murky. Writing in DIA’s Global Forum…

France Etienne Tichit has dedicated over five years to steering Novo Nordisk France through a transformative period of unprecedented growth and strategic realignment. His tenure has been marked by bold industrial investments exceeding EUR 2.3 billion, the establishment of France as a global manufacturing hub for next-generation diabetes and obesity treatments,…

Alexion Dana Vigier, Regional Vice President at Alexion, AstraZeneca Rare Disease blends clinical training as a French general practitioner with broad pharmaceutical leadership experience. Formerly President of the French Pharma Association in Oncology and a Global Franchise leader at AstraZeneca, she now oversees Alexion’s operations across Central and Northern Europe, including…

Global The CGT field is undergoing a critical transformation from boom to thoughtful reset. While early enthusiasm brought a rush of investment and regulatory attention, the sector is now refining its ambitions, weeding out unviable approaches, and laying the foundations for long-term impact. Companies, regulators, and healthcare systems are rethinking what…

USA Rich Bendis, CEO and founder of BioHealth Innovation, discusses how the BioHealth Capital Region has grown into a leading US life sciences hub by connecting Maryland, Washington, D.C., and Northern Virginia through a regional, collaborative approach. From supporting early-stage companies with non-dilutive funding and strategic mentoring to helping international firms…

Switzerland 2024 marked a transformative year for Switzerland’s regulatory authority, Swissmedic. As part of its ambitious 2023–2026 strategy, the agency made significant strides towards digital transformation and improving access to innovative medicines while delivering a notable 12 percent increase in new drug approvals with 46 new active substances. Drive for Digital…

Japan Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) concluded FY 2024‑25 (April 2024–March 2025) with a total of 148 approval decisions, including no less than 66 new active ingredients and 82 lifecycle updates, including new indications, pediatric expansions, and formulation changes. Innovation Snapshot A steady stream of orphan and rare‑disease designations—including sparsentan for primary…

Global Whether in the corridors of the FDA or the fast-evolving frameworks of ANVISA in Brazil, regulators around the world are undergoing a quiet revolution. While mature markets like the US and Europe double down on digitalisation and real-world evidence, emerging players like Brazil and China are accelerating access and joining…

Switzerland Urs Indermühle sees 2025 shaped by three big shifts and two urgent risks: R&D is now mostly sourced externally (just 35 percent developed in‑house), forcing pharma to master licensing and ecosystem partnerships; Asia, especially China, has become a serious innovation hub, making global IP and footprint strategies a priority; and…